Sertindole: Efficacy and safety in schizophrenia

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 13, 2006, Pages 1825-1834

  Lindström, Eva ^a   Levander, Sten ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Atypical antipsychotics; Schizophrenia; Sertindole

Indexed keywords

IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; SERTINDOLE;

ANIMAL; CLASSIFICATION; DRUG TOXICITY; ECONOMICS; HEALTH; HUMAN; PATHOLOGY; REVIEW; SCHIZOPHRENIA;

ANIMALS; DRUG TOXICITY; HEALTH; HUMANS; IMIDAZOLES; INDOLES; SCHIZOPHRENIA;

EID: 33846565809     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.13.1825     Document Type: Review

References (87)

1. WIDERLÖV B, BORGÅ P, CULLBERG J, STEFANSSON C-G, LINDQVIST G: Epidemiology of long-term functional psychosis in three different areas in Stockholm County. Acta Psychiatr. Scand. (1989) 80:40-46. (Pubitemid 19179475)
2. WIDERLÖV B: Långvarig funktionell psykos-epidemuiologi, vårduttnyttjande och sociala förhållanden i tre demografiskt skilda områden. [Long-term functional psychosis - epidemiology, need of care and social circumstanses in three different demographic areas. Master exam in social work]. Licenciatuppsats i socialt arbete (1990).
3. MCGRATH JJ: Variations in the incidence of schizophrenia: data versus dogma. Schizophr. Bull. (2006) 32:195-197. (Pubitemid 43063834)
4. LINDSTRÖM E, WIDERLÖV B, VON KNORRING L: The ICD-10 and DSM-IV diagnostic critera and the prevalence of schizophrenia. Eur Psychiatry (1997) 12:217-223. (Pubitemid 27298914)
5. WIESELGREN I-M: Prognosis and early prognostic factors in schizophrenia. Thesis. Uppsala University (1995).
6. GOVERNMENTAL COMMITTEE OF PSYCHIATRY: Welfare and free choice: Stockholm. Allmänna förlaget (1992):73.
7. LECOMTE P, DE HERT M, VAN DIJK M, NUIJTEN M, NUYTS G, PERSSON U: A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbation in Belgium. Value Health (2000) 3(1):1-11. (Pubitemid 30232943)
8. CHUE PS, HEEG B, BUSKENS E, VAN HOUT BA: Modelling the impact of complience on the costs and effects of long-acting risperidone in Canada. Pharmacoeconomics (2005) 23(Suppl. 1):62-74.
9. LINDSTRÖM E: The hidden costs of schizophrenia. J. Drug Dev. Clin. Pract. (1996) 7:281-288.
10. BROWN CS, MARKOWITZ JS, MOORE TR et al.: Atypical antipsychotics (Pt II): adverse effects, drug interactions, and costs. Ann. Pharmacother. (1999) 33(2):210-217. (Pubitemid 29109684)
11. NABER D, LAMBERT M: Sertindole decreases hospitalization and improves the quality of life of schizophrenic patients. Int. J. Psychiatry Clin. Pract. (1998) 2(Suppl. 2):73-77. (Pubitemid 128691839)
12. DELAY J, DENIKER P: Methodes chimiotherapiques en psychiatrie. Masson et Cie, Paris (1961).
13. LUBLIN H, EBERHARD J, LEVANDER S: Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int. Clin. Psychopharmacol. (2005) 20:183-198 • A description of unmet needs in schizophrenia, seldom discussed.
14. MOREL: Traite des maladies mentales (1860).
15. KRAEPELIN E: Dementia Praecox and paraphrenia. Krieger, New York (1919).
16. BLEULER E: Dementia Praecox oder die Gruppe der Schizophrenien. Leipzig-Wein: Aschaffenburgs Handbuch der Psychiiatrie, 1911. Translated into English by H Zinkin: Dementia Praecox or the Group of Schizophrenias. International New York, Universities Press, 1950.
17. SCHNEIDER K: Klinische Psychopathologie. Translated by MW Hamilton. Grune and Statton, New York (1959).
18. MAYER-GROSS W: In: Handbuch der Geisteskrankheiten 10. Bumke O (Ed). Springer-Verlag (1932).
19. KAY SR, SEVY S: Pyramidacal model of schizophrenia. Schizophr. Bull. (1990) 16:537-544.
20. BELL MD, LYSAKER PH, BEAM-GOULET JL, MILSTEIN RM, LINDENMAYER JP: Five-component model of schizophrenia: assessing the factorial invariance of the positive and negative syndrome scale. Psychiatry Res. (1994) 52(3):295-303. (Pubitemid 24225427)
21. LINDENMAYER JP, BERNSTEIN-HYMAN R, GROCHOWSKI SP: Five-factor model of schizophrenia. Initial validation. J. Nerv. Ment. Dis. (1994) 182(11):631-638.
22. GREEN MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry (1996) 153:321-330. •• Good explanation of cognitive defects in schizophrenia.
23. KANE J, HONIGFELD G, SINGER J, MELTZER H AND THE CLOZARIL COLLABORATIVE STUDY GROUP: Clozapine for the treatment-resistant schizophrenic: a double-blind camparison with chlorpromazine. Arch. Gen. Psych. (1988) 45:789-796.
24. BUCHANAN RW, BREIER A, KIRKPATRICK B, BALL P, CARPENTER WT Jr: Positive and negative symptome response to clozapine in schizophrenic patients with and without the deficit syndrome. Am. J. Psychiatry (1998) 155:751-760. (Pubitemid 28252653)
25. LIEBERMAN JA, STROUP TS, MCEVOY JP et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. (2005) 353:1209-1223. (Pubitemid 41345943)
26. LINDSTRÖM E, EBERHARD J, LEVANDER S: Five years follow-up during antipsychotic treatment: efficacy, safety and social outcome. Acta Psychiatr. Scand. (submitted).
27. HEATON RK, CROWLEY TJ: Effects of psychiatric disorders and their somatic treatment on neuropsychological test results. In: Handbook of Clinical Neuropsychology. Filskov SB Boll TJ (Eds) Wiley Press, New York (YEAR):481-525.
28. MEDALIA A, GOLD JM, MERRIAM A: The effects of neuroleptics on neuropsychological test results of schziophrenics. Arch. Clin. Neuropsychol. (1988) 3:249-271. (Pubitemid 18201018)
29. SPOHN HE, STRAUSS ME: Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenics. J. Abnorm. Psychol. (1989) 98:367-380. (Pubitemid 20066209)
30. CASSENS G, INGLIS AK, APPELBAUM PS, GUTHEIL TG: Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophrenia Bull (1990) 16:477-499.
31. KING DJ: The effcet of neuroleptics on cognitive and psychomotor function. Br. J. Psychirty (1990) 157:799-811.
32. BILDER RM, TURKEL E, LIPSCHULTZ-BROCH L, LIEBERMAN JA: Antipsychotic medication effects on neuropsychological functions. Psychophamacol. Bull. (1992) 28:353-366. (Pubitemid 23089722)
33. GRÅWE RW, LEVANDER S: Smooth pursuit eye movements and neuropsychological impairments in schizophrenia. Acta Psychiatr. Scand. (1995) 92:108-114.
34. GREEN MF, NUECHTERLINE KH et al.: Approaching a consensus cognitive battery for clinical trials in schizophrenia. Biol. Psychiatry (2004) 56:301-307.
35. LEVANDER S: Central cognitive deficits in schizophrenia. In: Cognition and schizophrenia: improving real life function. Morgan K, Murray R et al. (Eds). Cambridge University Press (2006).
36. LEUCHT S, WAHLBECK K, HAMANN J, KISSLING W: New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and metaanalysis. Lancet (2003) 362(9381):404; author reply 404-405. (Pubitemid 36578993)
37. EBERHARD J, LINDSTRÖM E, LEVANDER S: Tardive dyskinesia and neuroleptics - a 5-year longitudinal study of frequency, correlates and course. Int. Clin. Psychopharmacol. (2006) 21(1):35-42. (Pubitemid 43175121)
38. KLAWANS HL: The psychopharmacology of tardive dyskinesia. Am. J. Psychiatry (1973) 130:82-86.
39. GERLACH J, CASEY DE: Tardive dyskinesia. Acta Psychiatr. Scand. (1988) 77(4):369-378.
40. LIEBERMAN JA, SALTZ BL, JOHNS CA, POOACL S, BORENSTEIN M, KANE J: The effects of clozapine on tardive dyskinesia. Br. J. Psychiatry (1991) 158:503-510.
41. TAMMINGA CA, THAKER GK, MORAN M, KAKIGI T, GAO XM: Clozapine in tardive dyskinesia: observations from human and animal models. J. Clin. Psychiatry (1994) 55(Suppl.):102-106. (Pubitemid 24353029)
42. SPIVAK B, MESTER R, ABESGAUS J et al.: Clozapine treatment for neuroleptic-indiced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J. Clin. Psychiatry (1997) 58(7):318-322. (Pubitemid 27362488)
43. EMSLEY R, TURNER HJ, SCHRONEN J, BOTHA K, SMIT R, OOSTHUIZEN PP: A single-blind, randomized clinical trial comparing quetiapine and haloperidole in the treatment of tardive dyskinesia. J. Clin. Psychiatry (2004) 65(5):696-701.
44. PERQUIN L: Treatment with sertindole for late-occuring undesirable movements. Int. Clin. Psychopharmacol. (submitted).
45. TUNE LE, STRAUSS ME, LEW MF, BREITLINGER E, COYLE JT: Serumlevels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am. J. Psychiatry (1982) 139:1460-1462.
46. MOORE N: Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int. J. Psychiatry Clin. Pract (2002) 6 Suppl. 1:3-9.
47. RAGGI MA, MANDRIOLI R, SABBIONI C, PUCCI V: Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interaction. Curr. Med. Chem. (2004) 11(3):279-296. (Pubitemid 38240208)
48. ANDREWS G, HALL W, GOLDSTEIN G: The economic costs of schizophrenia. Implications for public policy. Arch. Gen. Psychiatry (1985) 42:537-543. (Pubitemid 15058329)
49. RICE DP, KELMAN S, MILLER LS: The economic costs of alcohol and drug abuse and mental illness. National Institute of Mental Health. Rockville, MD (1990).
50. DAVIES LM, DRUMMOND MF: Economics and schizophrenia: the real cost. Br. J. Psychiatry Suppl. (1994) 165(Suppl. 25):18-21. (Pubitemid 24331669)
51. EUROPEAN PARLIAMENT SESSION DOCUMENTS: Reports of the Committee on Energy, Research and Technology. Seligman M (1992).
52. LINDSTRÖM E, EBERHARD J, MILESSON FORS B, HANSEN K, SAPIN C, LAUNOIS R: A pharmacoeconomic analysis of schizophrenia management in Sweden. Abstract. Presented at the 14th European Congress of Psychiatry. Nice, France (2006).
53. LEWIS R, BAGNALL AM, LEITNER M: Sertindole for schizophrenia. Cochrane Database Syst Rev (2005) 20(3):CD001715.
54. AZORIN J-M, STRUB N, LOFT H: A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int. Clin. Psychopharmacol. (2006) 21:49-56. (Pubitemid 43175123)
55. KONGSAMUT S, KANG J, CHEN XL, ROEHR J, RAMPE D: A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur. J. Pharmacol. (2002) 450(1):37-41 (Pubitemid 34899593)
56. HADDAD PM, ANDERSON IM: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs (2002) 62(11):1649-1671. (Pubitemid 34848372)
57. LINDSTRÖM E, ERIKSSON L, LEVANDER S: Suicide in psychosis. Nordic Journal of Psychiatry (submitted).
58. NORDSTRÖM A, DAHLGREN L, KULLGREN G: Victim reltions and factors triggering homicides committed by offenders with schizophrenia. Acta Psychiatr. Scand. (submitted).
59. NEOVIUS M, EBERHARD J, LINDSTRÖM E, LEVANDER S: Weight development in patients treated with risperidone snd other antipsychotics: a five-year naturalistic study. Acta Psychiatr. Scand. (submitted).
60. EBERHARD J, LINDSTRÖM E, HOLSTAD M, LEVANDER S: Prolactin response to treatment with risperidone and risperidone combined with other psychotropic drugs in patients with schizophrenia and other psychotic disorders. Acta Psychiatr. Scand. (In press).
61. PERQUIN L, STEINERT T: A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs (2004) 18(Suppl. 2):19-30. (Pubitemid 38858282)
62. ARNT J, SKARSFELDT T: Do novel antopsychotics have the similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology (1998) 18:63-101. (Pubitemid 28026679)
63. HERRICK-DAVIS K, GRINDE E, TEITLER M: Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxy-tryptamine2Creceptors. J. Pharmacol. Exp. Ther. (2000) 295(1):226-232. (Pubitemid 30746085)
64. HIETALA J, KOUPPOAMÄKI M, MAJASUO H et al.: Sertindole is a serotonin 5-HT2C inverse agonist and decreases agonist but not antagonist binding to 5-HT2C receptors after chronic treatment. Psychopharmacology (2001) 157(2):180-187. (Pubitemid 32802130)
65. KASPER S, TAUSHER J, KUFFERLEE B: Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine, and haloperidole: a 123I-IBZM SPECT study. Psychopharmacology (1998) 136:367-373. (Pubitemid 28189666)
66. PILOWSKY LS, O'CONELL P, DAVIES N et al.: In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole: a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacol. (1997) 130:152-158. (Pubitemid 27132761)
67. ZIPURSKY RB, CHRISTENSEN BK, DASKALAKIS Z et al.: Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis. Can. J. Psychiatry (2005) 50(8):462-469. (Pubitemid 43161799)
68. LINDSTRÖM E, FARDE L, EBERHARD J, HAVERKAMP W: QTc interval prolongation and antipsychotic drug treatment: focus on sertindole. Int. J. Neuropsychopharmacol. (2005) 8:615-629. (Pubitemid 41400893)
69. HAVERKAMP W, ECKARDT L, MATZ J: Sertindole: cardiac electropsysiological profile. Int. J. Psychiatry Clin. Pract. (2002) 6(Suppl. 1):11-20. • A very intersting article explaining the mechanisms behind QT prolongation.
70. THOMSEN MB, VOLDERS PGA, STENGL M et al.: Electrophysiological safety of sertindole in dogs with normal and remodelled hearts. J. Pharmacol. Exp. Ther. (2003) 307(2):776-784. (Pubitemid 37310695)
71. WONG SL, SEBREE T, GRANNEMAN GR: Dose-proportionality of sertindole after 4-16 mg single-dose oral administration (abstact no. PPDM 8438). Pharm. Res. (1996) 13(9 Suppl.):502.
72. WONG SL, LINNEN P, MACK R et al.: Effects of food, antacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole on healthy volonteers. Biopharm. Drug Dispos. (1997) 18(6):533-541. (Pubitemid 27338984)
73. WONG SL, CAO G, MACK RJ et al.: Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clin. Pharmacol. Ther. (1997) 62(2):157-164. (Pubitemid 27373463)
74. WONG SL, MENACHERRY S, MULFORD D et al.: Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur. J. Clin. Pharmacol. (1997) 52:223-227. (Pubitemid 27278378)
75. MARKOWITZ JS, BROWN CS, MOORE TR: Atypical antipsychotics. Part 1: pharmacology, pharmacokinetics, and efficacy. Ann. Pharmacother. (1999) 33(1):73-85. (Pubitemid 29056560)
76. KANE JM, TAMMINGA CA: Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin. Invest. Drugs (1999) 6(11):1729-1741.
77. KAY SR: The positive and negative syndrome scale for schizophrenia (PANSS). Schizophrenia Bull (1987) 13:261-276. (Pubitemid 18039085)
78. VAN KAMMEN DP, MCEVOY JP, TARGUM SD et al.: A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (1996) 124(1-2):168-175. (Pubitemid 26112786)
79. ZIMBROFF DL, KANE JM, TAMMINGA CA et al.: Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. J. Psychiatry (1997) 154(6):782-791. (Pubitemid 27230100)
80. HALE A, AZORIN J-M, KASPER S et al.: Sertindole improves both the negative and positive symptoms of schizophrenia: results from a Phase III trial. Int. J. Psychiatry Clin. Pract. (2000) 4:55-62. (Pubitemid 30198337)
81. DANIEL DG, WOZNIAK P, MACK RJ et al.: Long term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol. Bull. (1998) 34(1):61-69. (Pubitemid 28176303)
82. KANE JM, POTKIN S, BUCKLEY P: Safety and efficacy of sertindole and risperidone in treatment of resistant patients with schizophrenia (abstact and poster). 10th International Congress on Schizophrenia Research. Savannah, GA (2005).
83. SCHUCK P, VAN DEN AMEELE H, JAANSON P, RYCKMANS V, HAWLEY C: Case histories illustating the utility of sertindole in clinical practice. CNS Drugs (2004) 18(Suppl. 2):31-43. (Pubitemid 38858283)
84. BROWN S: Excess mortality of schizophrenia. A meta-analysis. Br. J. Psychiatry (1997) 171:502-508. (Pubitemid 27527317)
85. HARRIS EC, BARRACLOUGH B: Suicide as an outcome for mental disorders. A meta-analysis. Br. J. Psychiatry (1997) 170:205-228. (Pubitemid 27117683)
86. http://www.lundbeck.com Lundbeck A/S: Launch of Serdolect commenced in Europe (online). Accessed 20 January, 2006.
87. http://www.emc.medicines.org.uk Lundbeck A/S: Sertindole: summary of product characteristics (online). Accessed 23 November, 2005.